---
title: "Birks Group Inc. reports $93.1M in net sales & $36.5M gross profit for the 26-week period ending Sept 27, 2025, up 16.2% from last year. CEO credits strong retail performance & European acquisition for growth."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/268807500.md"
description: "Birks Group Inc. reported a 16.2% increase in net sales to $93.1 million and a 16.7% rise in gross profit to $36.5 million for the 26-week period ending September 27, 2025. The CEO attributed growth to strong retail performance and a European acquisition. Despite a net loss of $2.6 million, the company saw a 6.3% increase in comparable store sales. SG&A expenses were $33.0 million, and EBITDA was $4.8 million."
datetime: "2025-12-05T22:19:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/268807500.md)
  - [en](https://longbridge.com/en/news/268807500.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/268807500.md)
---

# Birks Group Inc. reports $93.1M in net sales & $36.5M gross profit for the 26-week period ending Sept 27, 2025, up 16.2% from last year. CEO credits strong retail performance & European acquisition for growth.

Birks Group Inc. reported their financial results for the twenty-six-week period ending September 27, 2025. They had net sales of $93.1 million, a 16.2% increase from the prior year. Comparable store sales increased by 6.3%. Gross profit was $36.5 million, a 16.7% increase, with a gross profit margin of 39.2%. SG&A expenses were $33.0 million, representing 35.4% of net sales. EBITDA was $4.8 million, and the operating loss was $0.2 million. The company reported a net loss of $2.6 million for the period. The increase in expenses was partially attributed to the acquisition of European Boutique. The Chairman praised the strong retail performance and product offerings, thanking the employees for their efforts.

### Related Stocks

- [BGI.US](https://longbridge.com/en/quote/BGI.US.md)

## Related News & Research

- [Regeneron Sinks 10% on Failed Phase 3 Melanoma Trial. What Comes Next for REGN Stock.](https://longbridge.com/en/news/286811938.md)
- [X-Energy is in a post-IPO slump. Why analysts say the nuclear stock can surge](https://longbridge.com/en/news/286929875.md)
- [Watch live: The Hill's Decision Desk 2026 – Data Nerds](https://longbridge.com/en/news/286910191.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [AMF Tjanstepension AB Increases Position in American Water Works Company, Inc. $AWK](https://longbridge.com/en/news/286869600.md)